Compare Schlumberger NV (SLB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Sanofi SA — how do they compare? Schlumberger NV trades at $46.77 (market cap $69.36B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SLB | SNY | |
|---|---|---|
Market Cap | $69.36B | $104.83B |
Sector | Energy | Health |
52-Week High | $58.01 | $52.34 |
52-Week Low | $31.72 | $41.33 |
Enterprise Value | $77.58B | $121.32B |
Dividend Yield | 2.54% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $46.59, down 0.85% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.26% net margin and 14.57% ROE, supported by $6.5B in operating cash flow. Recent strategic moves include a partnership with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC award, positioning SLB to capitalize on energy and AI infrastructure demand.
The outlook is cautiously optimistic with an 84.85% analyst buy rating and a $62.83 consensus price target implying 35% upside. Risks include oil price volatility and execution challenges in new ventures, but SLB's solid balance sheet and digital growth initiatives offer a compelling case for long-term investors amid near-term market weakness.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
